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Dihydrofolate reductases (DHFR) catalyze the metabolically-essential reduction of dihydrofolate in an early step 
of purine biosynthesis. DHFRs are a central target in the control of proliferative diseases, including microbial 
infections. Trimethoprim is an effective antibiotic with broad clinical utility worldwide, acting as a selective 
inhibitor of microbial DHFRs. However, its clinical utility is threatened by the emergence of Type II microbial 
dihydrofolate reductases (DfrB) that are natively trimethoprim-resistant. DfrBs confer transmissible antibiotic 
resistance in humans and livestock. Their unusual structure and mode of substrate binding will be presented. 
We have created and screened active-site combinatorial libraries of a DfrB to provide key insights into the 
mechanism of this enzymatic reduction (1, 2). Attempts to identify promiscuous substrates for reduction have 
provided leads for inhibitor design. To this effect, we initiated a drug discovery program for these emerging 
targets. Fragment-based inhibitor development led to design of symmetrical bis-benzimidazoles that exhibit 
micromolar inhibition of DfrB1 (3). We determined that all closely-related Type II DHFRs share similar activity 
and inhibition patterns, broadening the utility of these inhibitors to the entire enzyme class. Upon whole-genome 
sequencing of trimethoprim-resistant E. coli from clinical isolates, we identified a dfrB gene flanked by multiple 
resistance genes, supporting its clinical emergence (4). To further investigate the evolutionary origin of this 
resistance enzyme, we undertook metagenomic screening. We have identified distantly-related structural 
homologs which, despite sharing only weak sequence homology, exhibit a high potential for conferring bacterial 
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Figure 1 – The unique active site of the DfrB1 
tetramer (left) is competitively inhibited with a 
designed bisbenzimidazole-type inhibitor (right). 
